Why aren’t peptides FDA-approved if they work so well?

Many peptide medicines are FDA-approved, including semaglutide. The relevant question is why a particular experimental peptide has not earned approval for a particular use. Approval requires an evidence package showing that a defined drug product’s benefits outweigh its known risks for the intended use, with supporting manufacturing and quality information. A plausible mechanism or favorable animal study does not complete that process.[1][2]

For BPC-157, the available research does not establish an FDA-approved treatment for tendon healing. FDA has identified important gaps in human safety information and concerns involving impurities and immune reactions. A clinician’s unfamiliarity is not evidence that a treatment is ineffective, but popularity online is equally unable to establish efficacy. Funding and development decisions can affect which candidates are studied; they do not supply missing clinical results.[3]

Approval, prescribing, and compounding are separate concepts. A prescription for a compounded preparation does not make that preparation FDA-approved. Compounding may address a patient need under applicable rules, but it is not the same review pathway as an approved medicine. To evaluate a claim, look for the exact approved product and indication, then check whether the cited research actually matches the proposed use.[4]